MetaCap

Achieve Life Sciences (QUIT) vs VolitionRX (VNRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Achieve Life Sciences is the larger company by market cap ($573.2 million vs $5.8 million), about 98.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QUIT-23.20%VNRX-28.27%
+4%-13%-30%
Oct 7, 20261 yearNov 20, 2026
QUIT-24.97%VNRX-23.28%
+11%-8%-27%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QUIT versus VNRX key metrics
MetricQUITVNRX
Share price$5.56$0.1621
Market cap$573.25M$5.85M
1-day change-5.28%-1.58%
EPS (TTM)$-1.71$-2.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.73M
Revenue growth (YoY)—+40.04%
Net income (latest FY)$-54.65M$-23.36M
Operating margin—-1258.47%
Net margin—-1352.16%
52-week high$8.64$7.80
52-week low$2.62$0.1555
Distance from 52-week high-35.65%-97.92%
Analyst consensusstrong_buynone
Avg. price target upside+162.23%+8302.22%
Average volume1.38M9.57M
Shares outstanding103.10M36.08M
Employees2857
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Achieve Life Sciences is about 98.0 times larger than VolitionRX by market value ($573.25M vs $5.85M).

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

About VolitionRX

VNRX stock →

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 57 employees

QUIT vs VNRX FAQ

Which is bigger, Achieve Life Sciences or VolitionRX?

Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $5.85M for VolitionRX (VNRX).

Are Achieve Life Sciences and VolitionRX in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons